Comment from Connected Health Initiative

Summary: The Connected Health Initiative (CHI), a multistakeholder policy and legal advocacy organization, strongly supports the FDA's proposed pilot program to assess AI-enabled technologies in early-phase clinical trials. They advocate for a risk-based, lifecycle-oriented approach that aligns with the NIST AI Risk Management Framework and provide specific recommendations on trial scope, participant selection, and evaluation metrics to ensure safety and innovation.